A population-based study of high-grade gliomas and mutated isocitrate dehydrogenase 1

International Journal of Clinical and Experimental Pathology

Volumn 6, Issue 1, 2013, Pages 31-40

  Dahlrot, Rikke H ^a,b   Kristensen, Bjarne W ^a,b   Hjelmborg, Jacob ^b   Herrstedt, Jørn ^a,b   Hansen, Steinbjørn ^a,b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Glioblastoma; High grade gliomas; Isocitrate dehydrogenase 1 (IDH1); Population characteristics; Prognosis

Indexed keywords

IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; BRAIN TUMOR; CANCER GRADING; ENZYMOLOGY; FEMALE; GENETICS; GLIOBLASTOMA; GLIOMA; HIGH-GRADE GLIOMAS; HUMAN; ISOCITRATE DEHYDROGENASE 1(IDH1); KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; MUTATION; POPULATION AND POPULATION RELATED PHENOMENA; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; VERY ELDERLY;

GLIOBLASTOMA; HIGH-GRADE GLIOMAS; ISOCITRATE DEHYDROGENASE 1(IDH1); POPULATION CHARACTERISTICS; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; FEMALE; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 84870459187     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Lawrence YR, Mishra MV, Werner-Wasik M, Andrews DW, Showalter TN, Glass J, Shen X, Symon Z and Dicker AP. Improving prognosis of glioblastoma in the 21st century: Who has benefited most? Cancer 2011.
2. Ohgaki H and Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005; 64: 479-489.
3. Stupp R, Mason WP, van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E and Mirimanoff RO. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
4. Stupp R, Hegi ME, Mason WP, van Den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG and Mirimanoff RO. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-466.
5. Brandes AA and Monfardini S. The treatment of elderly patients with high-grade gliomas. Semin Oncol 2003; 30: 58-62.
6. Keime-Guibert F, Chinot O, Taillandier L, Cartalat-Carel S, Frenay M, Kantor G, Guillamo JS, Jadaud E, Colin P, Bondiau PY, Menei P, Loiseau H, Bernier V, Honnorat J, Barrie M, Mokhtari K, Mazeron JJ, Bissery A and Delattre JY. Radiotherapy for glioblastoma in the elderly. N Engl J Med 2007; 356: 1527-1535.
7. Kurimoto M, Nagai S, Kamiyama H, Tsuboi Y, Kurosaki K, Hayashi N, Origasa H and Endo S. Prognostic factors in elderly patients with supratentorial malignant gliomas. Neurol Med Chir (Tokyo) 2007; 47: 543-549.
8. Lutterbach J and Ostertag C. What is the appropriate radiotherapy protocol for older patients with newly diagnosed glioblastoma? J Clin Oncol 2005; 23: 2869-2870.
9. WHO Classification of Tumours of the Central Nervous System. Edited by Louis DN, Ohgaki H, Wiestler OD and Cavenee WK. International Agency for Research on cancer (IARC) 2007.
10. Casartelli G, Dorcaratto A, Ravetti JL, Sola S, Vitali A, Merlo DF and Frosina G. Survival of high grade glioma patients depends on their age at diagnosis. Cancer Biol Ther 2009; 8: 1719-1721.
11. Martinez R, Volter C and Behr R. Parameters assessing neurological status in malignant glioma patients: prognostic value for survival and relapse-free time. Br J Neurosurg 2008; 22: 557-562.
12. Watne K, Hannisdal E, Nome O, Hager B and Hirschberg H. Prognostic factors in malignant gliomas with special reference to intra-arterial chemotherapy. Acta Oncol 1993; 32: 307-310.
13. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D and Sawaya R. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001; 95: 190-198.
14. Shirai K and Chakravarti A. Towards personalized therapy for patients with glioblastoma. Expert Rev Anticancer Ther 2011; 11: 1935-1944.
15. Kim KJ, Lee KH, Kim HS, Moon KS, Jung TY, Jung S and Lee MC. The presence of stem cell marker-expressing cells is not prognostically significant in glioblastomas. Neuropathology 2011.
16. Iliadis G, Kotoula V, Chatzisotiriou A, Televantou D, Eleftheraki AG, Lambaki S, Misailidou D, Selviaridis P and Fountzilas G. Volumetric and MGMT parameters in glioblastoma patients: survival analysis. BMC Cancer 2012; 12: 3.
17. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C and von DA. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 2008; 116: 597-602.
18. Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, Frattini M, Molinari F, Knowles M, Cerrato A, Rodolfo M, Scarpa A, Felicioni L, Buttitta F, Malatesta S, Marchetti A and Bardelli A. IDH1 mutations at residue p. R132 (IDH1(R132)) occur frequently in highgrade gliomas but not in other solid tumors. Hum Mutat 2009; 30: 7-11.
19. Combs SE, Rieken S, Wick W, Abdollahi A, von DA, Debus J and Hartmann C. Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back? Radiat Oncol 2011; 6: 115.
20. Mellai M, Piazzi A, Caldera V, Monzeglio O, Cassoni P, Valente G and Schiffer D. IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors. J Neurooncol 2011; 105: 345-357.
21. Takano S, Tian W, Matsuda M, Yamamoto T, Ishikawa E, Kaneko MK, Yamazaki K, Kato Y and Matsumura A. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing. Brain Tumor Pathol 2011; 28: 115-123.
22. Capper D, Weissert S, Balss J, Habel A, Meyer J, Jager D, Ackermann U, Tessmer C, Korshunov A, Zentgraf H, Hartmann C and von DA. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 2010; 20: 245-254.